Terrance G Johns

Terrance G Johns

UNVERIFIED PROFILE

Are you Terrance G Johns?   Register this Author

Register author
Terrance G Johns

Terrance G Johns

Publications by authors named "Terrance G Johns"

Are you Terrance G Johns?   Register this Author

71Publications

1321Reads

21Profile Views

MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells.

Cancers (Basel) 2020 Mar 11;12(3). Epub 2020 Mar 11.

School of Medical Sciences, Charles Perkins Centre and Faculty of Medicine and Health, The University of Sydney, NSW 2006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12030654DOI Listing
March 2020

Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial.

J Clin Neurosci 2019 Dec 30;70:157-163. Epub 2019 Sep 30.

Prince of Wales Clinical School, Cure Brain Cancer Biomarkers and Translational Research Group, University of New South Wales, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2019.08.044DOI Listing
December 2019

Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors.

Pharmacol Res 2018 08 23;134:166-178. Epub 2018 Jun 23.

The University of Sydney, Faculty of Medicine and Health, Charles Perkins Centre, NSW 2006, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2018.06.023DOI Listing
August 2018

A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.

Neoplasia 2018 05 22;20(5):432-442. Epub 2018 Mar 22.

Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia; Department of Pediatric Oncology and Hematology, Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia; Division of Paediatrics, School of Medicine, University of Western Australia, Crawley, Western Australia, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.02.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916087PMC
May 2018

Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.

Cancer Immunol Immunother 2017 Sep 13;66(9):1217-1228. Epub 2017 May 13.

Department of Medicine/Cardiology (Austin Health, Heidelberg), University of Melbourne, Lance Townsend Building, Level 10, Austin Campus, Studley Road, Heidelberg, VIC, 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-017-2013-zDOI Listing
September 2017

Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent.

ACS Med Chem Lett 2017 Apr 15;8(4):395-400. Epub 2017 Mar 15.

School of Medical Sciences and Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.6b00483DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392771PMC
April 2017

Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.

J Med Chem 2017 03 28;60(5):2052-2070. Epub 2017 Feb 28.

Oncogenic Signaling Laboratory, Centre for Cancer Research, Hudson Institute of Medical Research , 27 Wright Street, Clayton, Victoria 3168, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.6b01840DOI Listing
March 2017

Incomplete target neutralization by the anti-cancer antibody rilotumumab.

MAbs 2016 ;8(2):246-52

a Oncogenic Signalling Laboratory and Brain Cancer Discovery Collaborative, Centre for Cancer Research, Hudson Institute of Medical Research , 27-31 Wright Street, Clayton , VIC 3168 , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1122149DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966628PMC
December 2016

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma.

Sarcoma 2016 16;2016:3484673. Epub 2016 Oct 16.

Centre for Cancer Research, Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia; Monash University, Wellington Road, Clayton, VIC 3168, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2016/3484673DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5086398PMC
October 2016

EGFRvIII: the promiscuous mutation.

Cell Death Discov 2016 4;2:16049. Epub 2016 Jul 4.

Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia; Monash University, Clayton, Victoria 3800, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/cddiscovery.2016.49DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979472PMC
August 2016

Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.

Hypertension 2015 Dec 28;66(6):1251-9. Epub 2015 Sep 28.

From the Translational Obstetrics Group (K.R.P., T.J.K.-L., R.H., N.J.H., L.Y., N.B., P.C., L.T., S.T.) and Department of Obstetrics and Gynaecology(K.R.P., T.J.K.-L., R.H., N.J.H., L.Y., N.B., P.C., L.T., A.S., S.T.), University of Melbourne, Mercy Hospital for Women, Heidelberg, Victoria, Australia; and Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia (T.G.J.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.05883DOI Listing
December 2015

Targeted drug delivery using genetically engineered diatom biosilica.

Nat Commun 2015 Nov 10;6:8791. Epub 2015 Nov 10.

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia, Mawson Lakes Boulevard, Mawson Lakes, South Australia 5095, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms9791DOI Listing
November 2015

DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.

Pharmacol Ther 2015 Jul 17;151:87-98. Epub 2015 Mar 17.

Department of Pharmacology, School of Medical Sciences, University of Sydney, NSW 2006, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2015.03.004DOI Listing
July 2015

Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.

EJNMMI Res 2014 30;4:22. Epub 2014 May 30.

Ludwig Institute for Cancer Research, Austin Health, Melbourne 3084, Australia ; Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne 3084, Australia.

View Article

Download full-text PDF

Source
http://www.ejnmmires.com/content/4/1/22
Publisher Site
http://dx.doi.org/10.1186/s13550-014-0022-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070025PMC
July 2014

The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Tumour Biol 2014 Feb 26;35(2):1459-65. Epub 2013 Sep 26.

Prince of Wales Clinical School, Adult Cancer Program, Cure For Life Neuro-Oncology Group, Lowy Cancer Research Centre, University of New South Wales, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-013-1200-6DOI Listing
February 2014

The identification of mitochondrial DNA variants in glioblastoma multiforme.

Acta Neuropathol Commun 2014 Jan 2;2. Epub 2014 Jan 2.

Mitochondrial Genetics Group, Centre for Genetic Diseases, Monash Institute of Medical Research, Monash University, 27-31 Wright Street, Clayton, Victoria 3168, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2051-5960-2-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912901PMC
January 2014

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.

FEBS J 2013 Nov 8;280(21):5350-70. Epub 2013 Jul 8.

Tumour Targeting Program, Ludwig Institute for Cancer Research, Heidelberg, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/febs.12393DOI Listing
November 2013

Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.

Obstet Gynecol 2013 Oct;122(4):737-44

Translational Obstetrics Group, University of Melbourne, Mercy Hospital for Women, Heidelberg, the Ritchie Centre and the Centre for Cancer Research, Monash Institute of Medical Research, Monash University, and the Embryo Implantation Group, Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia; Department of Anatomy and Developmental Biology, Monash University, Clayton, Victoria, Australia; the 2nd Affiliated Hospital, Xian Jiatong University School of Medicine, Xian Jiatong, China; and the MRC Centre for Reproductive Health, The Queen's Medical Research Institute, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/greenjournal/2013/10000/Effects
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/AOG.0b013e3182a1ba56DOI Listing
October 2013

Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy.

Obstet Gynecol 2013 Oct;122(4):745-51

Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women, Heidelberg, and the Ritchie Centre and the Centre for Cancer Research, Monash Institute of Medical Research, Monash University, Clayton, Victoria, Australia; and the MRC Centre for Reproductive Health, the Queen's Medical Research Institute, Edinburgh, United Kingdom.

View Article

Download full-text PDF

Source
http://humrep.oxfordjournals.org/content/29/7/1375.full.pdf
Web Search
http://pdfs.journals.lww.com/greenjournal/2013/10000/Combina
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/AOG.0b013e3182a14cfbDOI Listing
October 2013

Targeting the ERBB family in cancer: couples therapy.

Nat Rev Cancer 2013 Sep 16;13(9):663-73. Epub 2013 Aug 16.

Ludwig Oncology Unit, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3559DOI Listing
September 2013

Antibody-functionalized porous silicon nanoparticles for vectorization of hydrophobic drugs.

Adv Healthc Mater 2013 May 30;2(5):718-27. Epub 2012 Nov 30.

Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-ENSCM-UM2-UM1, Ecole Nationale Supérieure de Chimie de Montpellier, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adhm.201200335DOI Listing
May 2013

A high-affinity ErbB4Fc fusion protein is a potent antagonist of heregulin-mediated receptor activation.

Growth Factors 2012 Oct 2;30(5):310-9. Epub 2012 Aug 2.

CSIRO Division of Materials Science and Engineering, 343 Royal Parade, Parkville, VIC 3052, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08977194.2012.709516DOI Listing
October 2012

A simple guide screw method for intracranial xenograft studies in mice.

J Vis Exp 2011 Sep 26(55). Epub 2011 Sep 26.

Monash Institute of Medical Research.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/3157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230180PMC
September 2011

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization.

J Cell Mol Med 2009 Sep 11;13(9B):3993-4001. Epub 2009 May 11.

Oncogenic Signalling Laboratory, Ludwig Institute for Cancer Research, Austin Health, Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1582-4934.2009.00783.x
Publisher Site
http://dx.doi.org/10.1111/j.1582-4934.2009.00783.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516546PMC
September 2009

Heparin-binding epidermal growth factor-like growth factor signaling in flow-induced arterial remodeling.

Circ Res 2008 May 24;102(10):1275-85. Epub 2008 Apr 24.

Department of Cell and Molecular Physiology, University of North Carolina, Chapel Hill, NC 27599-7545, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCRESAHA.108.171728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2752633PMC
May 2008

Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding.

Biochemistry 2007 Apr 24;46(15):4589-97. Epub 2007 Mar 24.

The Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, P.O. Box 2008, Royal Melbourne Hospital, Victoria 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi700002bDOI Listing
April 2007

The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.

Clin Cancer Res 2007 Mar;13(6):1911-25

Oncogenic Signalling Laboratory and Tumor Targeting Program, Ludwig Institute for Cancer Research, Melbourne Centre, Austin Hospital, Heidelberg, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-1453DOI Listing
March 2007

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806.

J Biol Chem 2007 Feb 8;282(5):2840-50. Epub 2006 Nov 8.

Oncogenic Signalling Laboratory, Ludwig Institute of Cancer Research, Austin Hospital, Level 6, Harold Stokes Building, Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M605136200DOI Listing
February 2007

Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury.

J Neurosci 2006 Jul;26(28):7532-40

Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.1004-06.2006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6674203PMC
July 2006

An automated peptide and protein thiazolidine coupling chemistry for biosensor immobilization giving a unique N-terminal orientation.

Anal Biochem 2006 Jan 26;348(2):315-7. Epub 2005 Sep 26.

Howard Florey Institute for Neuroscience, University of Melbourne, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000326970500670
Publisher Site
http://dx.doi.org/10.1016/j.ab.2005.09.006DOI Listing
January 2006

Functional effects of glycosylation at Asn-579 of the epidermal growth factor receptor.

Biochemistry 2005 Nov;44(45):14920-31

Department of Biological Sciences, Vanderbilt University, Nashville, Tennessee 37235, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi050751jDOI Listing
November 2005

The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor.

FASEB J 2005 May 17;19(7):780-2. Epub 2005 Mar 17.

Ludwig Institute for Cancer Research, Tumour Targeting Program, Austin Hospital, Heidelberg, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.04-1766fjeDOI Listing
May 2005

Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.

Cancer Immun 2005 Feb 22;5. Epub 2005 Feb 22.

Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, Austin Hospital, Heidelberg, Victoria, 3084, Australia.

View Article

Download full-text PDF

Source
February 2005

The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR.

Oncogene 2004 Aug;23(36):6095-104

Tumour Targeting Program, Ludwig Institute for Cancer Research, Melbourne Branch, Austin Hospital, Heidelberg 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207870DOI Listing
August 2004

The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis.

Proc Natl Acad Sci U S A 2003 Sep 5;100(19):11059-64. Epub 2003 Sep 5.

Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria 3168, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1833158100DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC196926PMC
September 2003

Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.

Hybrid Hybridomics 2003 Aug;22(4):219-28

Tumor Targeting Laboratory, Ludwig Institute for Cancer Research, Melbourne Tumor Biology Branch, Austin & Repatriation Medical Centre, 145-164 Studley Road, Heidelberg, Victoria 3084, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/153685903322328947DOI Listing
August 2003